Evidence tracker Pharmacology Delirium prevention

Dexmedetomidine to prevent postoperative delirium

Does perioperative dexmedetomidine prevent delirium, and in whom? Compare dosing and timing, cardiac versus noncardiac surgery, and delirium outcomes alongside bradycardia and hypotension.

Indexed papers
19
matching, retractions excluded
Randomized trials
4
plus 2 meta-analyses
With AI summary
19
others show original abstract
Registered, not results
0
ongoing trials
Clinical assessment not completed. No bottom line, certainty grade, or curated effect sizes have been written for this topic. Below is a source-linked inventory of matching papers (up to 200 from our cache), not a systematic review. Read the original studies before drawing conclusions.

Published studies

Open in feed

Recent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.

Showing 5 of 19 · Other

Recent evidence · past year

  1. Other Front Cardiovasc MedPublished 21 Sep 2026 Bom JS et al.
    Remimazolam versus dexmedetomidine-based sedation for transcatheter aortic valve implantation: hemodynamic stability and early clinical outcomes.
    AI summary of the abstract, unverified
    • A retrospective, single-center, propensity-matched cohort of 264 TAVI patients under monitored anesthesia care, 132 per group, was analyzed.
    • Remimazolam-based sedation was compared with dexmedetomidine-based sedation for intraprocedural hemodynamic instability.
    • Hemodynamic instability was less frequent with remimazolam (53.8% vs. 69.7%; adjusted OR 0.50, 95% CI 0.31-0.82; P = 0.006), driven mainly by fewer vasoactive treatments for hypotension.
    • Rescue midazolam use was much lower with remimazolam (1.5% vs. 43.2%), while respiratory events, conversion to general anesthesia, delirium, and 30-day outcomes did not differ.
    Original abstract (PubMed)

    BACKGROUND: Monitored anesthesia care (MAC) is increasingly used as part of minimalist transcatheter aortic valve implantation (TAVI) pathways, but evidence directly comparing remimazolam- and dexmedetomidine-based MAC with respect to intraprocedural hemodynamic stability and early clinical outcomes remains limited. METHODS: In this retrospective, single-center, propensity score-matched cohort study, 433 patients who underwent TAVI under MAC between January 2021 and May 2026 were identified. After 1:1 propensity score matching, 264 patients were included, with 132 patients in each group. The primary outcome was intraoperative hemodynamic instability, defined as bradycardia requiring anticholinergic treatment or hypotension requiring vasoactive treatment. Other outcomes included rescue midazolam use, respiratory adverse events, and early postoperative clinical outcomes. RESULTS: Remimazolam-based MAC was associated with less intraprocedural hemodynamic instability than dexmedetomidine-based MAC (53.8% vs. 69.7%; adjusted OR, 0.50; 95% CI, 0.31-0.82; P = 0.006), primarily reflecting less frequent vasoactive treatment for hypotension (50.8% vs. 67.4%; adjusted OR, 0.49; 95% CI, 0.30-0.81; P = 0.005). Bradycardia requiring anticholinergic treatment was numerically lower but not statistically significant. Rescue midazolam use was markedly lower with remimazolam (1.5% vs. 43.2%; P < 0.001). Respiratory adverse events, conversion to general anesthesia, postoperative delirium, length of stay, and 30-day clinical outcomes did not differ significantly between groups. CONCLUSIONS: In patients undergoing TAVI under MAC, remimazolam-based sedation was associated with a lower incidence of intraprocedural hemodynamic instability and less frequent rescue midazolam administration than dexmedetomidine sedation, without significant differences in early postoperative clinical outcomes.

  2. Other J Perianesth NursPublished 27 Aug 2026 Hamilton J et al.
    Intraoperative Dexmedetomidine Administration to Reduce Emergence Delirium and Narcotic Use in Pediatric Dental Patients.
    AI summary of the abstract, unverified
    • A quality improvement project with retrospective pre- and post-intervention data compared PACU narcotic use in pediatric dental patients.
    • The intervention combined an intraoperative dexmedetomidine bolus with evidence-based education bundles for PACU nurses and CRNAs.
    • Narcotic administration in the PACU decreased significantly after the intervention (p < 0.001), with no reported numeric effect size or confidence interval in the abstract.
    • The authors conclude the bundle reduced postoperative narcotic use, with no significant change in length of stay.
    Original abstract (PubMed)

    PURPOSE: This article describes methods of reducing emergence delirium, and subsequently narcotic administration, in the post-anesthesia care unit (PACU) using an intraoperative dexmedetomidine bolus and evidence-based education bundles. DESIGN: Quality improvement (QI) project including retrospective data analysis and evidence-based education bundle intervention. METHODS: Compared the administration of narcotics to pediatric dental patients pre- and post-intervention of intraoperative dexmedetomidine bolus and presentation of evidence-based education bundles to PACU nurses and certified registered nurse anesthetists (CRNAs). FINDINGS: The intervention of evidence-based education bundles and intraoperative dexmedetomidine bolus resulted in significant decrease (p < 0.001) in narcotic administration in the PACU. CONCLUSIONS: Implementation of intraoperative dexmedetomidine and perioperative staff education to prevent and identify emergence delirium for pediatric dental patients resulted in decreased postoperative narcotics administration in the PACU, although no significant change in length of stay.

  3. Other BMC AnesthesiolPublished 23 Jul 2026 Bishwokarma P et al.
    Anaesthetic challenges in a nonagenarian with Parkinson's disease undergoing hip fracture surgery: a case report.
    AI summary of the abstract, unverified
    • Single case report of one 93-year-old man with Parkinson's disease who underwent cemented hemiarthroplasty for a hip fracture, with a Newari-only language barrier.
    • Spinal anaesthesia used 3 mL of 0.5% hyperbaric bupivacaine with 5 µg intrathecal dexmedetomidine, chosen to prolong the block after discussion with the orthopaedic team.
    • Intraoperative hypotension (three episodes, treated with mephentermine) and hypoglycaemia (55 mg/dL) occurred, followed by transient delirium and aspiration pneumonia; discharged on postoperative day 10.
    • The authors conclude spinal anaesthesia was feasible and emphasise dose optimisation, glycaemic monitoring, continuing dopaminergic therapy, delirium prevention, and dysphagia-safe feeding.
    Original abstract (PubMed)

    BACKGROUND: Hip fractures in nonagenarian patients with multiple comorbidities present substantial anaesthetic challenges. Parkinson's disease (PD) adds further complexity through motor symptoms, autonomic dysfunction, and the imperative for uninterrupted dopaminergic therapy. CASE PRESENTATION: We report the perioperative anaesthetic management of a 93-year-old male with hypertension, Parkinson's disease, hypothyroidism, and dyslipidaemia who underwent cemented left hemiarthroplasty for a transcervical neck of femur fracture. The case was additionally complicated by a significant language barrier, as the patient was exclusively fluent in Newari. Spinal anaesthesia was administered at L3-L4 using 3 mL of 0.5% hyperbaric bupivacaine with 5 µg intrathecal dexmedetomidine, selected to prolong anaesthesia based on discussion with the orthopaedic team; the rationale and limitations of this dosing strategy are critically appraised in the Discussion. Intraoperatively, the patient developed three episodes of hypotension, likely related to sympathetic blockade and adjuvant effects, managed with incremental doses of mephentermine. An episode of intraoperative hypoglycaemia (blood glucose 55 mg/dL) was promptly corrected with 50% dextrose. Postoperatively, the patient developed transient hypoactive delirium due to temporary interruption of dopaminergic therapy, which resolved after resumption of enteral medications by postoperative day 2. On postoperative day 3, the patient developed aspiration pneumonia after oral feeding was initiated by family members despite a functioning nasogastric tube. The condition was managed with antibiotics and supportive care. The patient subsequently improved and was discharged on postoperative day 10. CONCLUSION: Spinal anaesthesia is feasible in nonagenarians with multiple comorbidities, including Parkinson's disease. This case highlights the need for evidence-based dose optimisation and proactive complication prevention. It further emphasises the importance of low-dose bupivacaine-based spinal anaesthesia in very elderly patients, meticulous perioperative glycaemic monitoring, continuation of dopaminergic therapy, structured delirium prevention strategies, caregiver education, and strict adherence to dysphagia-safe feeding protocols in high-risk geriatric patients.

  4. Other Exp NeurolPublished 30 Apr 2026 Chen N et al.
    Dexmedetomidine mitigates postoperative delirium in aged mice via TFEB-linked restoration of microglial lysosomal function and attenuated neuroinflammation.
    AI summary of the abstract, unverified
    • Preclinical study in aged mice using a laparotomy-with-visceral-manipulation model, comparing Sham, POD, and POD+DEX groups with behavioral, hippocampal, and primary microglia analyses.
    • Dexmedetomidine treatment was compared against untreated POD mice, with in vitro work using TFEB knockdown in LPS-stimulated primary microglia.
    • DEX improved POD-like behaviors and reduced microglial activation and pro-inflammatory cytokines, with increased lysosomal protein expression and TFEB nuclear translocation; no effect sizes or p values are reported in the abstract.
    • The authors conclude that TFEB activation may restore microglial lysosomal function and that enhancing lysosomal function could be a potential POD target; DEX also inhibited NLRP3 signaling, which TFEB knockdown substantially attenuated.
    Original abstract (PubMed)

    BACKGROUND: Postoperative delirium (POD) is a serious complication in elderly patients. Dexmedetomidine (DEX) can reduce POD incidence, but its neuroprotective mechanisms are unclear. This study investigated whether DEX alleviates POD-like phenotypes and whether hippocampal transcription factor EB (TFEB) contributes to this effect, with a focus on microglial lysosomal function. METHODS: An aged mouse POD model was established via laparotomy with visceral manipulation. Mice were assigned to Sham, POD, and POD+DEX groups. Behavioral tests assessed cognitive and affective functions. Hippocampal tissues were analyzed for neuroinflammation and lysosomal markers. Primary microglia were isolated for in vitro studies involving TFEB knockdown. RESULTS: DEX treatment significantly ameliorated POD-like behaviors and reduced hippocampal microglial activation and pro-inflammatory cytokine levels. DEX treatment was associated with increased lysosomal protein expression and promoted TFEB nuclear translocation in microglia, correlating with enhanced lysosomal gene transcription. In vitro, DEX increased lysosomal acidity and improved functional readouts in LPS-stimulated microglia in a TFEB-dependent manner, suggesting partial recovery of lysosome-dependent clearance. DEX also inhibited the NLRP3 inflammasome pathway, an effect substantially attenuated by TFEB knockdown. Mechanistically, DEX-mediated TFEB activation was associated with reduced mTOR activity. CONCLUSION: DEX mitigates POD-like phenotypes in aged mice, with evidence that TFEB activation in the hippocampus contributes to restoration of lysosomal function and attenuation of neuroinflammation. Microglia appear to be a key cellular compartment in this process. These findings suggest that enhancing lysosomal function may represent a potential target for POD.

  5. Other J Cardiothorac Vasc AnesthPublished 29 Apr 2026 Yılmaz Ş et al.
    Effects of Fixed-Dose Postoperative Dexmedetomidine on Delirium and Early Clinical Outcomes After Cardiovascular Surgery: A Retrospective Cohort Study of 408 Patients.
    AI summary of the abstract, unverified
    • Single-center retrospective cohort of 408 adults undergoing elective cardiovascular surgery (2022–2023), comparing a fixed postoperative dexmedetomidine infusion (n = 188) with no dexmedetomidine (n = 220).
    • Exposure was a 24-hour infusion at 0.2 μg/kg/h versus no postoperative dexmedetomidine, with delirium assessed by CAM-ICU at 6 and 24 hours.
    • Delirium was less frequent with dexmedetomidine at 6 hours (2.1% vs 7.0%, p = 0.032) and 24 hours (0.5% vs 3.6%, p = 0.042); adjusted OR at 6 hours was 0.25 (95% CI 0.07–0.88).
    • Dexmedetomidine was also linked to shorter extubation time (6.85 ± 1.49 vs 9.47 ± 5.61 hours, p < 0.001) and similar adverse events and mortality, though the authors call for prospective confirmation.
    Original abstract (PubMed)

    OBJECTIVES: Postoperative delirium (POD) is a frequent and serious complication after cardiovascular surgery and is associated with impaired recovery and worse clinical outcomes. Dexmedetomidine has been suggested to reduce delirium risk; however, evidence from real-world cardiac surgery cohorts remains inconsistent. This study evaluated the association between a fixed-dose postoperative dexmedetomidine infusion and delirium incidence, sedation depth, and early clinical outcomes. DESIGN: Single-center retrospective cohort study. SETTING: Tertiary cardiovascular surgery center. PARTICIPANTS: A total of 408 adult patients undergoing elective cardiovascular surgery between January 2022 and December 2023. INTERVENTIONS: Patients received either a fixed-dose dexmedetomidine infusion (0.2 μg/kg/h for 24 hours, n = 188) or no dexmedetomidine (control group, n = 220) in the postoperative period. MEASUREMENTS AND MAIN RESULTS: POD was assessed using the Confusion Assessment Method for the ICU at 6 and 24 hours, and sedation depth was assessed using the Richmond Agitation-Sedation Scale. Dexmedetomidine use was associated with a lower incidence of POD at 6 hours (2.1% v 7.0%, p = 0.032) and 24 hours (0.5% v 3.6%, p = 0.042). Multivariable logistic regression identified dexmedetomidine as an independent factor associated with reduced delirium risk at 6 hours (adjusted odds ratio, 0.25; 95% confidence interval, 0.07-0.88). In addition, patients receiving dexmedetomidine demonstrated deeper and more stable sedation profiles and shorter extubation times (6.85 ± 1.49 hours v 9.47 ± 5.61 hours, p < 0.001), with reduced postoperative analgesic requirements. Hemodynamic adverse events, major complications, and early and 30-day mortality rates were similar between groups. CONCLUSIONS: In this retrospective cohort study, fixed low-dose dexmedetomidine infusion after cardiovascular surgery was associated with a lower observed incidence of early POD, improved sedation profiles, faster extubation times, and reduced analgesic requirements without increased adverse events. These findings suggest that dexmedetomidine may be associated with improved early postoperative recovery in selected cardiac surgery patients. Prospective studies are needed to confirm these findings and further clarify the role of dexmedetomidine in perioperative care.

Earlier evidence / dates not confirmed

Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.

  1. No matching papers in this section with the selected filters.

Ongoing registrations

From ClinicalTrials.gov

Registrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.

No registered ongoing trials found.